Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

105.60 -2.40 (-2.22%)
Streaming Delayed Price Updated: 1:47 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
57 58 Next >
News headline image
GE HealthCare's Solid Demand And Sensible Margin Targets: Morgan Stanley Sees Potential Upside Despite Street's High Expectations ↗
Morgan Stanley analyst Patrick Wood initiated coverage on GE HealthCare Technologies Inc (NASDAQ: GEHC) with an Equal-Weight rating and a  
Via Benzinga
News headline image
Dexcom, A Top 2% Stock, Raises 2025 Outlook Amid 'Rapidly' Expanding Diabetes Market ↗
The company makes continuous glucose monitors for patients with diabetes. 
Via Investor's Business Daily
News headline image
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Agilent Technologies Stock: Ready to Rise off the Floor
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider. 
Via MarketBeat
News headline image
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next. 
Via MarketBeat
News headline image
Looking At Abbott Laboratories's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Looking At Abbott Laboratories's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval ↗
The FDA has approved Surmodics Inc's (NASDAQ: SRDX) SurVeil drug-coated balloon (DCB), a next-generation device  
Via Benzinga
News headline image
3 Passive Income Stocks to Hold for the Next 20 Years ↗
These three stocks are likely to keep increasing their dividends over years or even decades. 
Via The Motley Fool
News headline image
Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application ↗
In an investor presentation, Surmodics Inc (NASDAQ: SRDX) said it submitte 
Via Benzinga
News headline image
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip ↗
Recent troubles won't stop these companies' long-term trajectories. 
Via The Motley Fool
News headline image
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed' ↗
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga
News headline image
Looking At Abbott Laboratories's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
(ABT) - Analyzing Abbott Laboratories's Short Interest ↗
 
Via Benzinga
News headline image
A Look Into Abbott Laboratories Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Abbott Laboratories Unusual Options Activity For May 10 ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning 
Via MarketBeat
News headline image
Nvidia Chief Flags Dangers To US Chips Act, Disney, Shell, Gucci Allegedly Used Worthless Carbon Credits, Microsoft's Daring Attempt to Outshine Google In Search Game: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process ↗
 
Via Benzinga
News headline image
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market ↗
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
News headline image
Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy ↗
U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Abbott Laboratories (NYSE: ABT) Similac and other formulas that they said had... 
Via Benzinga
News headline image
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter ↗
Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' < 
Via Benzinga
News headline image
Back Off, Chronic Pain! FDA Nods for Abbott's Spinal Cord Stimulation Devices ↗
The FDA approved Abbott Laboratories (NYSE: ABT) spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as  
Via Benzinga
News headline image
Claims of PediaSure Boosting Children's Height Challenged in Lawsuit Against Abbott Laboratories ↗
A New York City woman has reportedly sued Abbott Laboratories (NYSE: ABT), accusing them of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase... 
Via Benzinga
News headline image
Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks ↗
Here are seven must-have dividend stocks for long-term investing that you can consider for your dividend stock portfolio. 
Via InvestorPlace
News headline image
Cramer Asks Investors To Focus On Individual Stocks Over Macro Strategies: Says Don't 'Miss The Trees For The Forest' ↗
 
Via Benzinga
News headline image
3 Dividend Stock Warning Signs That Could Portend Trouble ↗
Recognizing these red flags will help you avoid investing in weaker businesses. 
Via The Motley Fool
News headline image
Is Dexcom a Good Stock to Buy Now? ↗
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it. 
Via The Motley Fool
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.